Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$16.76 +0.06 (+0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$16.75 -0.01 (-0.06%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$16.42
$17.20
50-Day Range
$10.64
$18.93
52-Week Range
$5.14
$29.46
Volume
444,386 shs
Average Volume
443,817 shs
Market Capitalization
$903.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 46% of companies evaluated by MarketBeat, and ranked 622nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Upstream Bio has received no research coverage in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

  • Price to Book Value per Share Ratio

    Upstream Bio has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Upstream Bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for UPB.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UPB.
  • News Sentiment

    Upstream Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for UPB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UPB Stock News Headlines

Trump’s AI Agenda: The 9 stocks poised to benefit most
While many are busy chasing the usual AI trends, a bigger opportunity is quietly brewing—and most are missing it. Imagine a major shift in how and where AI is built, opening up incredible wealth opportunities for those in the know. I’ve found 9 AI companies primed to lead this change. These aren’t the tired “AI hype” stocks; they’re companies with real US operations, proven revenue growth, and deep AI integration.tc pixel
Upstream Bio (UPB) Q2 R&D Soars 169%
Upstream Bio, Inc. reports Q2 results
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB stock has increased by 1.9% and is now trading at $16.76.

Upstream Bio, Inc. (NASDAQ:UPB) posted its earnings results on Wednesday, August, 6th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.13. The firm earned $0.94 million during the quarter, compared to the consensus estimate of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative trailing twelve-month return on equity of 35.90%.

Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

Top institutional shareholders of Upstream Bio include Bain Capital Life Sciences Investors LLC (4.53%), Norges Bank (1.80%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.54%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
CIK
2022626
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$38.00
Potential Upside/Downside
+234.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.81 million
Net Margins
-3,836.58%
Pretax Margin
-3,836.58%
Return on Equity
-35.90%
Return on Assets
-26.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
38.27
Quick Ratio
38.27

Sales & Book Value

Annual Sales
$2.37 million
Price / Sales
383.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.58 per share
Price / Book
2.23

Miscellaneous

Outstanding Shares
53,910,000
Free Float
46,599,000
Market Cap
$909.46 million
Optionable
N/A
Beta
N/A

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners